LAMICTAL XR Drug Patent Profile

Which patents cover Lamictal Xr, and when can generic versions of Lamictal Xr launch?

Lamictal Xr is a drug marketed by Glaxosmithkline Llc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has forty-four patent family members in thirty countries.

The generic ingredient in LAMICTAL XR is lamotrigine. There are thirty-two drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lamictal Xr

A generic version of LAMICTAL XR was approved as lamotrigine by DR REDDYS LABS LTD on January 22^nd, 2009.

Summary for LAMICTAL XR

International Patents:	44
US Patents:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LAMICTAL XR

Paragraph IV (Patent) Challenges for LAMICTAL XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LAMICTAL XR	Extended-release Tablets	lamotrigine	25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg	022115	1	2014-02-12

US Patents and Regulatory Information for LAMICTAL XR

LAMICTAL XR is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-001	May 29, 2009	AB	RX	Yes	No			Y
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-004	May 29, 2009	AB	RX	Yes	Yes			Y
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-002	May 29, 2009	AB	RX	Yes	Yes			Y
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-003	May 29, 2009	AB	RX	Yes	No			Y
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-005	Apr 14, 2010	AB	RX	Yes	No			Y

International Patents for LAMICTAL XR

See the table below for patents covering LAMICTAL XR around the world.

Country	Patent Number	Title	Estimated Expiration
African Intellectual Property Organization (OAPI)	12770	Oral dosage form controlled drug release.
Iceland	7707	Efnablöndur með tafða losun sem innihalda lamótrígín
South Korea	100882707
Taiwan	200307567
Israel	163098	ORAL DOSAGE FORM FOR CONTROLLED DRUG RELEASE

LAMICTAL XR Market Analysis and Financial Projection

Last updated: April 25, 2026

LAMICTAL XR (lamotrigine extended-release): Investment Scenario and Fundamentals Analysis

What is LAMICTAL XR and how is it positioned commercially?

LAMICTAL XR is the extended-release formulation of lamotrigine for the treatment of epilepsy. It is marketed in the US under Bausch Health (formerly Valeant; brand ownership sits within Bausch/its affiliates following the U.S. neurology franchise rollups).

Key commercial framing

• Core MOA: lamotrigine is a sodium-channel blocker and stabilizes neuronal membranes, reducing excitability.
• Formulation strategy: XR (extended-release) supports more stable plasma exposure versus immediate-release.
• Indication economics: lamotrigine is long-established; pricing and volume growth are constrained by generic penetration, with XR value driven by differentiated dosing experience and prescriber preference where substitution barriers exist.

Which product attributes matter to investors?

LAMICTAL XR’s investment profile is driven by three fundamentals: patent/IP headwinds, payer economics under generic pressure, and manufacturing/launch execution versus competitors.

Fundamental	What to watch	Investor signal
IP protection	Composition, formulation, and method claims; exclusivity; authorized generics	Timeline to meaningful erosion and whether barriers persist beyond label expansions
Competitive set	Immediate-release generics; other XR/alternative antiepileptics	Share durability and ability to hold net price after formulary shifts
Net revenue quality	Rebate intensity, channel inventory, D&A of contract pricing	Whether revenue declines track volume or pricing collapse
Supply chain	Finished goods stability, batch success rate	Whether there are stoppages or recall-driven swings

---

Is the IP wall strong or does LAMICTAL XR face generic pressure?

What does the patent landscape imply for durability?

LAMICTAL XR is a formulation in a mature active ingredient category. In practice, investors should treat lamotrigine generics as a constant pressure baseline, with LAMICTAL XR value depending on the extent of enforceable exclusivity around XR-specific claims (formulation, release profile, or method-of-use) and whether competitors can launch with design-arounds.

What investors typically infer from a mature API + XR brand

• The API is off-patent in most markets.
• XR protection is the remaining lever, and its value usually compresses over time as courts and FDA pathway dynamics clarify enforceability.
• The most material question is not “is there a patent,” but “does any enforceable XR-specific claim meaningfully delay competition.”

---

What are the demand fundamentals in epilepsy that affect LAMICTAL XR volume?

How does epilepsy market structure support or cap growth?

Epilepsy demand is stable with chronic patients and ongoing incident cohorts, but brand growth depends on:

• Patient persistence on a tolerated and effective regimen
• Switching costs (titration, adverse-event history, and physician familiarity)
• Payor protocols that push generic substitution

For LAMICTAL XR, the XR advantage tends to matter most at the margin:

• Patients stable on XR resist switching.
• New prescriptions can be more elastic if payers require immediate-release generics first line.

---

How does payer economics shape LAMICTAL XR net revenue?

What does generic competition do to pricing and rebates?

In a mature antiepileptic market, brand-to-generic substitution usually drives:

• Gross-to-net compression through rebates and patient assistance strategies
• Formulary tiering (preferred vs non-preferred)
• Utilization management such as step edits

For investors, the signature is:

• Unit growth without revenue growth indicates net price degradation.
• Revenue decline faster than units indicates rebate escalation.

---

What does LAMICTAL XR’s competitive landscape look like?

Who competes with LAMICTAL XR?

LAMICTAL XR competes primarily against:

• Generic immediate-release lamotrigine
• Other branded antiepileptics with payor pull in certain formularies
• Alternative dosing regimens (extended-release options, though lamotrigine XR is a narrower class)

Competitor group	Typical payer position	Likely impact on LAMICTAL XR
Generic lamotrigine IR	Preferred due to cost	Persistent share pressure
Other branded anti-epileptics	Depends on specialty mix and contracting	Threat varies by health plan
Therapeutic switching	Protocol-driven	In-year volatility if step edits tighten

---

What is the investment scenario: base, bull, bear?

Base case

• Revenue drifts downward as generic substitution continues.
• LAMICTAL XR holds a residual base of patients benefiting from XR dosing and tolerability.
• Net revenue erosion tracks both price and mix rather than a sudden collapse.

Bull case

• XR-specific positioning remains defensible via prescriber preference and limited substitution in high-persistence subpopulations.
• Regulatory or legal outcomes reduce near-term generic entry risk.
• Share stabilizes and net pricing holds longer than expected.

Bear case

• Increased formulary tightening accelerates IR substitution.
• Any adverse IP outcome or design-around increases competitive intensity.
• Net price declines faster than units, compressing gross-to-net and profitability.

---

What fundamentals determine whether the shares react positively or negatively?

Investable KPI set

Investors should focus on the metrics that show whether LAMICTAL XR is losing on price, losing on volume, or losing both.

KPI	Why it matters	Direction to watch
Net revenue trajectory	Captures rebates and pricing	Revenue stability vs sustained decline
Prescription trends (TRx)	Shows utilization shifts	TRx decline faster than market implies share loss
Gross-to-net trend	Identifies rebate pressure	Rising rebates signal payor tightening
Launch timing of generics/authorized generics	Impacts cadence of erosion	Accelerated erosion after entry events
SG&A and gross margin	Indicates operating leverage	Margin compression signals revenue quality issues

---

What investor diligence should focus on for LAMICTAL XR?

Diligence checklist for an R&D or capital allocation decision

1. Timeline mapping: consolidate all XR-specific exclusivity end points and any litigation-driven delays.
2. Formulary and contracting: track whether major plans keep LAMICTAL XR on preferred tiers or move it to non-preferred.
3. Channel inventory: ensure no supply overhang that can cause sudden sell-in spikes followed by later corrections.
4. Patient mix: evaluate whether declines are concentrated in new starts (more substitutable) versus chronic continuations (less substitutable).
5. Lifecycle management: ensure marketing and access strategies are tuned to gross-to-net dynamics.

---

Key Takeaways

• LAMICTAL XR is a lamotrigine extended-release brand in a mature antiepileptic category where generic pressure is structural.
• The investment outlook depends on whether XR-specific exclusivity or practical formulary barriers delay substitution beyond what a typical XR lifecycle would predict.
• Fundamentals should be interpreted through net revenue quality (gross-to-net) and utilization (TRx), not just gross sales.
• The most sensitive variables are IP/litigation timing and payer contracting that drive both net price and patient persistence.

---

FAQs

1) What drives LAMICTAL XR’s revenue most directly?

Net price and persistence. Generic substitution pressures both pricing and patient starts; the XR advantage tends to matter most for patients already stabilized on XR.

2) Does LAMICTAL XR growth come from new patients or switching?

It depends on contracting. In most models, switching contributes more than net new incidence because payers push generic immediate-release as default.

3) What indicator best signals accelerating erosion?

Gross-to-net expanding while units flatten, indicating rebate escalation and tougher formulary placement.

4) Is the competitive threat mainly immediate-release generics?

Yes. The dominant economic substitute is generic lamotrigine immediate-release, with other antiepileptics acting as plan-dependent alternatives.

5) What is the key event risk for investors?

Any legally or regulatorily enabled increase in generic competition intensity (including design-arounds) and major payor formulary changes affecting XR placement.

---

References

[1] U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book).
[2] U.S. Food and Drug Administration. Drug Approval Package / Label information for LAMICTAL XR (lamotrigine extended-release). (Accessed via FDA labeling/archives).
[3] Centers for Medicare & Medicaid Services. Medicare Part D drug utilization and spending context (public data sources). (Accessed via CMS datasets/summary publications).
[4] Bausch Health. Investor materials and product franchise disclosures related to neurology assets. (Accessed via company filings and presentations).